NEW YORK, NY, July 18, 2016--Intranasal flu vaccines may be able to provide long-lasting protection against pandemic flu strains, according to a new study from immunologists at Columbia University Medical Center (CUMC).
The researchers found that, in mice, the intranasal flu vaccine FluMistTM (Medimmune) led to the production of T cells in the lungs that provided long-term protection against multiple flu strains, including those that were not present in the vaccines. Mice given the traditional injectable vaccine, such as FluzoneTM (Sanofi Pasteur), did not produce these cells.